Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion

Giampaolo Niccoli, Andrea Celestini, Camilla Calvieri, Nicola Cosentino, Elena Falcioni, Roberto Carnevale, Cristina Nocella, Francesco Fracassi, Marco Roberto, Roberta P. Antonazzo, Pasquale Pignatelli, Filippo Crea, Francesco Violi

Research output: Contribution to journalArticle

Abstract

Background: Persistent oxidative stress may play a key role in microvascular obstruction (MVO). We aimed at assessing the role of platelet gp91phox (NOX2), the catalytic subunit of NADPH oxidase in MVO. Methods: We enrolled 40 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention within 12 h from symptoms onset, either with angiographic MVO (n=20) or good angiographic myocardial reperfusion (MR) (n=20). Angiographic MVO was defined as a final thrombolysis in myocardial infarction (TIMI) flow ≤2 or TIMI flow of 3 with myocardial blush grade 2α showed a trend to increase from baseline to pre-discharge in angiographic MVO patients (295 (183.50-389.25) pmol/l vs 322 (206-370) pmol/l, p=0.06), but not in patients with MR (p=0.56), with a trend for interaction between baseline and pre-discharge levels among the two groups (p=0.09). Conclusion: Patients with MVO, but not those with myocardial reperfusion, have a sustained increase of NOX2 and 8-iso-PGF. Therapies targeting NOX2 or high dosage antioxidants should be tested for MVO prevention and treatment.

Original languageEnglish
Pages (from-to)379-388
Number of pages10
JournalEuropean Heart Journal: Acute Cardiovascular Care
Volume2
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

Percutaneous Coronary Intervention
Myocardial Reperfusion
Reperfusion
Oxidative Stress
Myocardial Infarction
Dinoprost
NADPH Oxidase
Catalytic Domain
Blood Platelets
Antioxidants
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. / Niccoli, Giampaolo; Celestini, Andrea; Calvieri, Camilla; Cosentino, Nicola; Falcioni, Elena; Carnevale, Roberto; Nocella, Cristina; Fracassi, Francesco; Roberto, Marco; Antonazzo, Roberta P.; Pignatelli, Pasquale; Crea, Filippo; Violi, Francesco.

In: European Heart Journal: Acute Cardiovascular Care, Vol. 2, No. 4, 2013, p. 379-388.

Research output: Contribution to journalArticle

Niccoli, G, Celestini, A, Calvieri, C, Cosentino, N, Falcioni, E, Carnevale, R, Nocella, C, Fracassi, F, Roberto, M, Antonazzo, RP, Pignatelli, P, Crea, F & Violi, F 2013, 'Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion', European Heart Journal: Acute Cardiovascular Care, vol. 2, no. 4, pp. 379-388. https://doi.org/10.1177/2048872613504698
Niccoli, Giampaolo ; Celestini, Andrea ; Calvieri, Camilla ; Cosentino, Nicola ; Falcioni, Elena ; Carnevale, Roberto ; Nocella, Cristina ; Fracassi, Francesco ; Roberto, Marco ; Antonazzo, Roberta P. ; Pignatelli, Pasquale ; Crea, Filippo ; Violi, Francesco. / Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. In: European Heart Journal: Acute Cardiovascular Care. 2013 ; Vol. 2, No. 4. pp. 379-388.
@article{4c6c421be01749e4b3b067f3deff5f00,
title = "Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion",
abstract = "Background: Persistent oxidative stress may play a key role in microvascular obstruction (MVO). We aimed at assessing the role of platelet gp91phox (NOX2), the catalytic subunit of NADPH oxidase in MVO. Methods: We enrolled 40 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention within 12 h from symptoms onset, either with angiographic MVO (n=20) or good angiographic myocardial reperfusion (MR) (n=20). Angiographic MVO was defined as a final thrombolysis in myocardial infarction (TIMI) flow ≤2 or TIMI flow of 3 with myocardial blush grade 2α showed a trend to increase from baseline to pre-discharge in angiographic MVO patients (295 (183.50-389.25) pmol/l vs 322 (206-370) pmol/l, p=0.06), but not in patients with MR (p=0.56), with a trend for interaction between baseline and pre-discharge levels among the two groups (p=0.09). Conclusion: Patients with MVO, but not those with myocardial reperfusion, have a sustained increase of NOX2 and 8-iso-PGF2α. Therapies targeting NOX2 or high dosage antioxidants should be tested for MVO prevention and treatment.",
author = "Giampaolo Niccoli and Andrea Celestini and Camilla Calvieri and Nicola Cosentino and Elena Falcioni and Roberto Carnevale and Cristina Nocella and Francesco Fracassi and Marco Roberto and Antonazzo, {Roberta P.} and Pasquale Pignatelli and Filippo Crea and Francesco Violi",
year = "2013",
doi = "10.1177/2048872613504698",
language = "English",
volume = "2",
pages = "379--388",
journal = "European Heart Journal: Acute Cardiovascular Care",
issn = "2048-8726",
publisher = "Sage Publications",
number = "4",

}

TY - JOUR

T1 - Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion

AU - Niccoli, Giampaolo

AU - Celestini, Andrea

AU - Calvieri, Camilla

AU - Cosentino, Nicola

AU - Falcioni, Elena

AU - Carnevale, Roberto

AU - Nocella, Cristina

AU - Fracassi, Francesco

AU - Roberto, Marco

AU - Antonazzo, Roberta P.

AU - Pignatelli, Pasquale

AU - Crea, Filippo

AU - Violi, Francesco

PY - 2013

Y1 - 2013

N2 - Background: Persistent oxidative stress may play a key role in microvascular obstruction (MVO). We aimed at assessing the role of platelet gp91phox (NOX2), the catalytic subunit of NADPH oxidase in MVO. Methods: We enrolled 40 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention within 12 h from symptoms onset, either with angiographic MVO (n=20) or good angiographic myocardial reperfusion (MR) (n=20). Angiographic MVO was defined as a final thrombolysis in myocardial infarction (TIMI) flow ≤2 or TIMI flow of 3 with myocardial blush grade 2α showed a trend to increase from baseline to pre-discharge in angiographic MVO patients (295 (183.50-389.25) pmol/l vs 322 (206-370) pmol/l, p=0.06), but not in patients with MR (p=0.56), with a trend for interaction between baseline and pre-discharge levels among the two groups (p=0.09). Conclusion: Patients with MVO, but not those with myocardial reperfusion, have a sustained increase of NOX2 and 8-iso-PGF2α. Therapies targeting NOX2 or high dosage antioxidants should be tested for MVO prevention and treatment.

AB - Background: Persistent oxidative stress may play a key role in microvascular obstruction (MVO). We aimed at assessing the role of platelet gp91phox (NOX2), the catalytic subunit of NADPH oxidase in MVO. Methods: We enrolled 40 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention within 12 h from symptoms onset, either with angiographic MVO (n=20) or good angiographic myocardial reperfusion (MR) (n=20). Angiographic MVO was defined as a final thrombolysis in myocardial infarction (TIMI) flow ≤2 or TIMI flow of 3 with myocardial blush grade 2α showed a trend to increase from baseline to pre-discharge in angiographic MVO patients (295 (183.50-389.25) pmol/l vs 322 (206-370) pmol/l, p=0.06), but not in patients with MR (p=0.56), with a trend for interaction between baseline and pre-discharge levels among the two groups (p=0.09). Conclusion: Patients with MVO, but not those with myocardial reperfusion, have a sustained increase of NOX2 and 8-iso-PGF2α. Therapies targeting NOX2 or high dosage antioxidants should be tested for MVO prevention and treatment.

UR - http://www.scopus.com/inward/record.url?scp=84906908543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906908543&partnerID=8YFLogxK

U2 - 10.1177/2048872613504698

DO - 10.1177/2048872613504698

M3 - Article

C2 - 24338297

AN - SCOPUS:84906908543

VL - 2

SP - 379

EP - 388

JO - European Heart Journal: Acute Cardiovascular Care

JF - European Heart Journal: Acute Cardiovascular Care

SN - 2048-8726

IS - 4

ER -